Research Advances of Immunotherapy of Exosome PD-L1 in Non-small Cell Lung Cancer
Cancer immunotherapy is increasingly popular in the field of cancer treatment, and related research is emerging. For patients with non-small cell lung cancer (NSCLC), in recent years, immune checkpoint inhibitors (ICIs) represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-09-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.33 |
| _version_ | 1798000205651509248 |
|---|---|
| author | Na WANG Xia SONG |
| author_facet | Na WANG Xia SONG |
| author_sort | Na WANG |
| collection | DOAJ |
| description | Cancer immunotherapy is increasingly popular in the field of cancer treatment, and related research is emerging. For patients with non-small cell lung cancer (NSCLC), in recent years, immune checkpoint inhibitors (ICIs) represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants, have become one of the most promising treatments for malignant tumors. Immune checkpoint blockade therapy includes anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mAb, anti-PD-1 mAb and anti-PD-L1 mAb, with the best-known number of PD-L1 immunotherapy. At present, ICIs have achieved very good therapeutic results in clinical treatment, but with less effective efficiency, so we hope to obtain higher therapeutic efficiency. In recent years, exosomal PD-L1 has played an important role in the progress of immunotherapy for NSCLC. This paper reviews the effects of tumor exosomal PD-L1 protein on the tumor microenvironment, the effect prediction of immunotherapy, and as novel therapeutic strategies for immunotherapy in NSCLC. |
| first_indexed | 2024-04-11T11:16:29Z |
| format | Article |
| id | doaj.art-cb20a66367f242d1bf915db04cf9a7bd |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-11T11:16:29Z |
| publishDate | 2022-09-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-cb20a66367f242d1bf915db04cf9a7bd2022-12-22T04:27:11ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872022-09-0125968969510.3779/j.issn.1009-3419.2022.102.33Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung CancerNa WANG0Xia SONG1The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, ChinaThe Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030000, ChinaCancer immunotherapy is increasingly popular in the field of cancer treatment, and related research is emerging. For patients with non-small cell lung cancer (NSCLC), in recent years, immune checkpoint inhibitors (ICIs) represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants, have become one of the most promising treatments for malignant tumors. Immune checkpoint blockade therapy includes anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mAb, anti-PD-1 mAb and anti-PD-L1 mAb, with the best-known number of PD-L1 immunotherapy. At present, ICIs have achieved very good therapeutic results in clinical treatment, but with less effective efficiency, so we hope to obtain higher therapeutic efficiency. In recent years, exosomal PD-L1 has played an important role in the progress of immunotherapy for NSCLC. This paper reviews the effects of tumor exosomal PD-L1 protein on the tumor microenvironment, the effect prediction of immunotherapy, and as novel therapeutic strategies for immunotherapy in NSCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.33exosomepd-l1lung neoplasmsimmunotherapy |
| spellingShingle | Na WANG Xia SONG Research Advances of Immunotherapy of Exosome PD-L1 in Non-small Cell Lung Cancer Chinese Journal of Lung Cancer exosome pd-l1 lung neoplasms immunotherapy |
| title | Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer |
| title_full | Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer |
| title_fullStr | Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer |
| title_full_unstemmed | Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer |
| title_short | Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer |
| title_sort | research advances of immunotherapy of exosome pd l1
in non small cell lung cancer |
| topic | exosome pd-l1 lung neoplasms immunotherapy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.33 |
| work_keys_str_mv | AT nawang researchadvancesofimmunotherapyofexosomepdl1innonsmallcelllungcancer AT xiasong researchadvancesofimmunotherapyofexosomepdl1innonsmallcelllungcancer |